A5006403678- Prostate Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Hormonal and reproductive studies
- Urological Disorders and Treatments
- Urologic and reproductive health conditions
- Bladder and Urothelial Cancer Treatments
- DNA Repair Mechanisms
- PARP inhibition in cancer therapy
- Urinary Bladder and Prostate Research
- Reconstructive Surgery and Microvascular Techniques
- Pelvic floor disorders treatments
- Radiomics and Machine Learning in Medical Imaging
- Cancer, Lipids, and Metabolism
- Urinary and Genital Oncology Studies
- Cardiac, Anesthesia and Surgical Outcomes
- Sexual Differentiation and Disorders
- Renal cell carcinoma treatment
- Estrogen and related hormone effects
- Cancer Diagnosis and Treatment
- Virtual Reality Applications and Impacts
- Systemic Sclerosis and Related Diseases
- Renal and Vascular Pathologies
- Employment, Labor, and Gender Studies
- Advanced biosensing and bioanalysis techniques
- Spaceflight effects on biology
Vall d'Hebron Hospital Universitari
2021-2025
Universitat Autònoma de Barcelona
2016-2024
Hebron University
2021-2024
Illumina (United States)
2023
Vall d'Hebron Institute of Oncology
2022
Highlights•RAD51-IF is feasible in FFPE clinical biopsies from patients with advanced prostate cancer•Low RAD51 scores associate alterations BRCA1/2•Low improved outcomes PARPi or platinum chemotherapy•RAD51-IF captures HRR restoration of function upon drug resistanceSummaryMetastatic cancer (mPC) enriched for homologous recombination repair (HRR) gene alterations, which have prognostic and predictive value. Routine implementation next-generation sequencing (NGS) still limited. We...
The aim of this study was to evaluate hormonal recovery after cessation androgen deprivation therapy (ADT) in a group elderly prostate cancer patients.Forty patients with locally advanced or metastatic cancer, mean age 71.5 years [95% confidence interval (CI) 69.1-73.9], were treated ADT for duration 74.6 months (95% CI 59.7-89.5 months). Mean follow-up time 36.5 30.6-42.3 Serum testosterone and luteinizing hormone (LH) determined at 6 month intervals cessation.After 18 follow-up, all had...
The correct identification of extracapsular extension (ECE) prostate cancer (PCa) on multiparametric magnetic resonance imaging (mpMRI) is crucial for surgeons in order to plan the nerve-sparing approach radical prostatectomy. Nerve-sparing strategies allow better outcomes preserving erectile function and urinary continence, notwithstanding this can be penalized with worse oncologic results. aim study was assess ability preoperative mpMRI predict ECE final prostatic specimen (PS) identify...
TPS209 Background: Multiple lines of evidence suggest a crosstalk between androgen receptor (AR) signaling and DNA damage repair (DDR) in prostate cancer. Co-targeting both pathways mHNPC can result clinically relevant synergistic effect. ZZFIRST trial is evaluating the combination TALA –a poly(ADP-ribose) polymerase inhibitor– EZ –an AR patients. Methods: This multicenter, open-label, randomized, investigator-initiated phase 2 clinical trial. Men aged ≥18 years with histologically confirmed...
Abstract Purpose Metastatic prostate cancer (mPC) is enriched for homologous recombination repair (HRR) gene alterations; these biomarkers have prognostic and predictive value. Next-generation sequencing (NGS) allows patient stratification based on biomarkers, but widespread clinical implementation still limited. Moreover, not all mutations in HRR genes result functional loss the tumor. We investigated correlation between genomic of HRR, using NGS an optimized RAD51 immunofluorescence...
Pelvic lymph node dissection (PLND) is the most accurate procedure for (LN) staging in prostate cancer (PCa) patients. LN sectioning and hematoxylin eosin (H&E) staining of at least one slice remains gold standard evaluation, potentially leading to misdetection small metastatic focus. Entire analysis possible with One-Step Nucleic Acid Amplification (OSNA) by detecting cytokeratin 19 (CK19) mRNA as a surrogate invasion. This study aimed compare postoperative performance OSNA pooling...
You have accessJournal of UrologyProstate Cancer: Localized: Surgical Therapy I1 Apr 2018MP05-04 ANATOMICAL BENCHMARKS IN PREOPERATIVE MAGNETIC RESONANCE IMAGING PREDICT EARLY CONTINENCE RECOVERY FOLLOWING ROBOTIC RADICAL PROSTATECTOMY Lucas Regis, Merce Cuadras, Enric Miret, Ricardo Lopez, Aina Salazar, Sarai Roche, Ana Celma, David Lorente, Jose Placer, Jacques Planas, Enrique Trilla, and Juan Morote RegisLucas Regis More articles by this author , CuadrasMerce Cuadras MiretEnric Miret...
You have accessJournal of UrologyProstate Cancer: Advanced (including Drug Therapy) II1 Apr 2018PD14-04 CHEMILUMINISCENT IMMUNOASSAYS SHOULD NOT BE USED TO MEASURE SERUM TESTOSTERONE IN PROSTATE CANCER PATIENTS UNDERGOING ANDROGEN DEPRIVATION THERAPY Mercé Cuadras, Enric Miret, Ricardo López, Imma Comas, Roser Ferrer, Jacques Planas, Ana Celma, Xavier Maldonado, Joan Carles, Lucas Regis, and Juan Morote CuadrasMercé Cuadras More articles by this author , MiretEnric Miret LópezRicardo López...